# Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line Chemotherapy

> **NCT02449655** · PHASE2 · TERMINATED · sponsor: **Samsung Medical Center** · enrollment: 27 (actual)

## Conditions studied

- Advanced Gastric Adenocarcinoma

## Interventions

- **DRUG:** AZD5363
- **DRUG:** paclitaxel
- **DRUG:** AZD2014
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT02449655
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-02-12
- **Primary completion:** 2018-07-16
- **Final completion:** 2018-07-16
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** lack of efficacy
- **Last updated:** 2019-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02449655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02449655, "Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line Chemotherapy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02449655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*